United-Guardian Reports 2025 Financial Results
Rhea-AI Summary
United-Guardian (NASDAQ:UG) reported FY2025 net sales of $10,545,468, down 13% from 2024, and net income of $2,105,738 ($0.46 per share) versus $3,250,875 ($0.71) in 2024. Sales of pharmaceuticals and medical lubricants rose, while cosmetic ingredient sales declined.
The company cited distributor inventory overstock, weaker China demand, and tariffs; it plans marketing and distribution initiatives, including additional Renacidin formulary placements.
Positive
- Pharmaceutical sales +15% in 2025
- Medical lubricant sales +4% in 2025
- Net income of $2.11M maintained despite sales decline
- Renacidin added to two major pharmacy benefit formularies
Negative
- Net sales down 13% to $10.55M in 2025
- Net income declined 35% year-over-year
- Income from operations fell to $2.24M from $3.65M
- Stockholders' equity decreased to $11.23M
Market Reaction – UG
Following this news, UG has gained 6.40%, reflecting a notable positive market reaction. Our momentum scanner has triggered 4 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $6.65. This price movement has added approximately $2M to the company's valuation. Trading volume is exceptionally heavy at 6.7x the average, suggesting very strong buying interest.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.
Key Figures
Market Reality Check
Peers on Argus
Pre-news, UG was up 0.64% while peers were mixed: RAY -2.34%, PHH -1.69%, TANH +2.32%, GROV -2.99%, DSY +3.7%, pointing to stock-specific drivers.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 06 | Q3 2025 earnings | Negative | -6.3% | Q3 and nine‑month 2025 sales and income declined versus prior year. |
| Aug 08 | Q2 2025 earnings | Negative | -0.5% | Q2 and H1 2025 revenue and net income fell year over year. |
| May 08 | Q1 2025 earnings | Negative | +0.6% | Sharp declines in sales and income driven by cosmetic ingredient weakness. |
| Mar 21 | FY 2024 earnings | Positive | -3.0% | FY 2024 delivered higher sales and net income with strong segment growth. |
| Nov 08 | Q3 2024 earnings | Positive | -12.1% | Q3 2024 and nine‑month results showed rising sales and earnings. |
Earnings releases often coincided with downside moves, including selloffs after strong FY 2024 and Q3 2024 results, while a weak Q1 2025 once saw a modest gain.
Over the past year, United-Guardian’s earnings updates have traced a shift from strength in 2024 to pressure in 2025. FY 2024 results showed higher sales and income, but subsequent 2025 quarters highlighted declining net sales and earnings, largely tied to softer cosmetic ingredient demand and China-related tariffs. Pharmaceutical and medical lubricant segments frequently showed growth. This FY 2025 release continues that narrative of overall financial pressure despite healthier non-cosmetic lines and ongoing efforts to expand Renacidin® formulary access.
Historical Comparison
Earnings headlines for UG have typically produced modest negative reactions, with an average move of -4.25%, even when fundamentals were improving.
Earnings history shows a turn from strong FY 2024 growth, driven by cosmetics and lubricants, to FY 2025 pressure as cosmetic ingredients softened while pharmaceuticals and lubricants provided partial offset.
Market Pulse Summary
The stock is up +6.4% following this news. A strong positive reaction aligns with the market’s tendency to reassess United-Guardian’s earnings in context of its segment mix. Past data show that even solid results sometimes met selling pressure, so a large gain after this update could reflect renewed confidence in growing pharmaceutical and medical lubricant lines. Investors would need to monitor whether cosmetic ingredient demand and China exposure continue to weigh on overall performance in subsequent periods.
Key Terms
pharmacy benefit managers regulatory
AI-generated analysis. Not financial advice.
HAUPPAUGE, N.Y., March 27, 2026 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) reported that net sales and net income for FY 2025 decreased compared to FY 2024. Net sales for the year decreased by
Donna Vigilante, President of United-Guardian, stated, “Our financial performance in 2025 was primarily impacted by the decrease in sales of our cosmetic ingredients. One of the issues we faced was excess inventory held by our largest cosmetic ingredient distributor, Ashland Specialty Ingredients (“ASI”). The inventory overstock led to reduced order quantities from ASI throughout the year. The situation was further impacted by decreased global demand for our products, particularly in China, where heightened competition from local Asian producers, and the impact of global tariffs, negatively impacted sales. In response to these challenges, we have been collaborating closely with our distributor in China to regain lost market share, offering competitive pricing where feasible, differentiating our products from the competition, and exploring new markets where cost pressures are less pronounced.”
“On a positive note, sales of pharmaceuticals and medical lubricants increased in 2025 compared to 2024, by
United-Guardian is a manufacturer of cosmetic ingredients, sexual wellness ingredients, pharmaceuticals, and medical lubricants.
| Contact: | Donna Vigilante |
| (631) 273-0900 | |
| dvigilante@u-g.com |
NOTE: This press release contains both historical and "forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements about the company’s expectations or beliefs concerning future events, such as financial performance, business prospects, and similar matters, are being made in reliance upon the “safe harbor” provisions of that Act. Such statements are subject to a variety of factors that could cause our actual results or performance to differ materially from the anticipated results or performance expressed or implied by such forward-looking statements. For further information about the risks and uncertainties that may affect the company’s business please refer to the company's reports and filings with the Securities and Exchange Commission.
| FINANCIAL RESULTS AS OF AND FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024 STATEMENTS OF INCOME | ||||||||
| Years ended December 31, | ||||||||
| 2025 | 2024 | |||||||
| Net sales | $ | 10,545,468 | $ | 12,181,971 | ||||
| Costs and expenses: | ||||||||
| Cost of sales | 5,404,328 | 5,721,584 | ||||||
| Operating expenses | 2,434,148 | 2,356,819 | ||||||
| Research and development | 463,644 | 456,779 | ||||||
| Total costs and expenses | 8,302,120 | 8,535,182 | ||||||
| Income from operations | 2,243,348 | 3,646,789 | ||||||
| Other income: | ||||||||
| Investment income | 365,308 | 434,679 | ||||||
| Net gain on marketable securities | 34,359 | 26,989 | ||||||
| Total other income | 399,667 | 461,668 | ||||||
| Income before provision for income taxes | 2,643,015 | 4,108,457 | ||||||
| Provision for income taxes | 537,277 | 857,582 | ||||||
| Net income | $ | 2,105,738 | $ | 3,250,875 | ||||
| Earnings per common share (basic and diluted) | $ | 0.46 | $ | 0.71 | ||||
| Weighted average shares (basic and diluted) | 4,594,319 | 4,594,319 | ||||||
| BALANCE SHEET DATA (condensed) | ||||||
| December 31, | ||||||
| 2025 | 2024 | |||||
| Current assets: | $ | 12,201,397 | $ | 12,665,551 | ||
| Deferred tax asset, net | --- | 175,397 | ||||
| Property, plant, and equipment, net | 907,182 | 956,387 | ||||
| Total assets | 13,108,579 | 13,797,335 | ||||
| Current liabilities: | 1,669,321 | 1,914,469 | ||||
| Deferred tax liability, net | 207,246 | --- | ||||
| Total liabilities | 1,876,567 | 1,914,469 | ||||
| Stockholders’ equity | 11,232,012 | 11,882,866 | ||||
| Total liabilities and stockholders’ equity | $ | 13,108,579 | $ | 13,797,335 | ||
FAQ
Why did United-Guardian (UG) report a 13% sales decline in FY2025?
How did United-Guardian (UG) achieve higher pharmaceutical sales in 2025?
What is the FY2025 EPS and net income reported by United-Guardian (UG)?
What actions is United-Guardian (UG) taking to recover cosmetic ingredient sales?
Did United-Guardian (UG) report any balance sheet or liquidity changes for 2025?
How might Renacidin formulary approvals affect United-Guardian (UG) going forward?
